免疫疗法“冲击”：一组程序性死亡受体配体1（PD-L1）表达为100%且帕博利珠单抗一线治疗的病例系列

Zarogoulidis Paul, Athanasiou Evaggelia, Tsiouda Theodora, Hatzibougias Dimitrios, Huang Haidong, Bai Chong, Trakada Georgia, Veletza Lemonia, Kallianos Anastasios, Kosmidis Christoforos, Barbetakis Nikolaos, Paliouras Dimitrios, Rapti Aggeliki, Drougas Dimitrios, Hohenforst-Schmidt Wolfgang

Pulmonary-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.

Private Pathology Center, "Microdiagnostics", Thessaloniki, Greece.

Respir Med Case Rep. 2017 Aug 29;22:197-202. doi: 10.1016/j.rmcr.2017.08.017. eCollection 2017.

In this decade a "bloom" of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.

在这十年间，人们观察到针对非小细胞肺癌的新型疗法“蓬勃发展”。我们有了诊断肺癌的新工具，而且在不同病变部位进行再次活检比以前更容易，还能获取组织样本，以调查患者是否可以接受新的靶向治疗。免疫疗法此前已在其他癌症形式中得到充分确立，如今在肺癌治疗中也有应用。目前有两种免疫疗法，即纳武单抗和帕博利珠单抗，它们可作为二线治疗药物使用，如果程序性死亡配体1表达≥50%，第二种药物也可作为一线治疗药物使用。